3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, T-Cell
1
Lymphoma
1
Liposarcoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hemangiosarcoma
1
Dermatofibrosarcoma
1
Interventions
Doxorubicin
33
Ifosfamide
23
Gemcitabine
19
pazopanib
18
Cyclophosphamide
16
Radiotherapy
15
pembrolizumab
13
Filgrastim
12
Docetaxel
12
Bevacizumab
10
Vincristine
9
Sirolimus
9
Irinotecan
9
Etoposide
9
olaratumab
7
eribulin
7
Sorafenib
7
Radiation
7
temsirolimus
6
Temozolomide
6
Mesna
6
Magnetic Resonance Spectroscopy
6
Cisplatin
6
tazemetostat
5
cixutumumab
5
Trabectedin
5
Radiosurgery
5
Nivolumab
5
Ipilimumab
5
Granulocyte Colony-Stimulating Factor
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Sarcoma
×
TTI-621
×
Clear all
NCT04996004
2024-12-11
TTI-621-03
Pfizer
Phase 2
Terminated
76 enrolled
53 charts